Sartorius AGSARTF 84 EV-to-EBIT is 37.60 as of Jul. 11, 2026, which is 3% above its 10-year median of 36.54. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $273.65 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 464 Medical Devices & Instruments companies, Sartorius AG ranks worse than 79.53% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sartorius AG's Enterprise Value for the quarter that ended in Mar. 2026 was $21,253 Mil.
Sartorius AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $589 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG EV-to-EBIT Related Terms
Sartorius AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Sartorius AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sartorius AG's EV-to-EBIT falls into.
Sartorius AG's current Enterprise Value is $22,158 Mil.
Sartorius AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $589 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a EV-to-EBIT of 37.60 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sartorius AG and its competitors. This is near median its historical median of 36.54. Over the past decade, Sartorius AG's EV-to-EBIT has ranged from 11.27 to 79.18. According to the industry distribution chart, Sartorius AG ranks #369 out of 464 companies in the Medical Devices & Instruments industry, placing it in the top 79.5%.
Is Sartorius AG's EV-to-EBIT too high?
Sartorius AG's current EV-to-EBIT of 37.60 is near median its 10-year median of 36.54. Over the past 10 years, this metric has ranged from a low of 11.27 to a high of 79.18. The Medical Devices & Instruments industry median EV-to-EBIT is 18.34. Sartorius AG's value of 37.60 is 105% above this industry median. Based on the distribution chart, Sartorius AG ranks #369 out of 464 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #369 out of 464 companies for EV-to-EBIT. This places Sartorius AG in the lower half of its industry. The industry median EV-to-EBIT is 18.34. Sartorius AG's value of 37.60 is 105% above this benchmark. Historically, Sartorius AG's own EV-to-EBIT has ranged from 11.27 to 79.18 over the past decade. While the company's 10-year median is 36.54 vs. the industry median of 18.34, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.34, based on 464 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EV-to-EBIT of 37.60 is 105% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EV-to-EBIT is 37.60, which is near median its own 10-year median of 36.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $273.65, compared to a current price of $212.80 — trading 22.2% below its estimated fair value. The current EV-to-EBIT is 37.60, which is near median its 10-year median of 36.54 and 105% above the Medical Devices & Instruments industry median of 18.34. Sartorius AG's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sartorius AG (SARTF), the current EV-to-EBIT is 37.60 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.2% below its estimated GF Value™ of $273.65.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
EV-to-EBIT: 37.60 (near median its 10-year median of 36.54)
GF Value™: $273.65 vs. price of $212.80 (22.2% below fair value)
Industry Position: 105% above the Medical Devices & Instruments median (#369 of 464)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
